

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[Home \(index.cfm?resetfields=1\)](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N021770

Product 001
BRIMONIDINE TARTRATE (ALPHAGAN P) SOLUTION/DROPS 0.1%

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	6562873*PED	01/10/2022					
001	6627210*PED	01/18/2022					
001	6641834*PED	01/28/2022					
001	6673337*PED	01/26/2022					
001	8858961	09/02/2023		DP			11/13/2014
001	8858961*PED	03/02/2024					
001	9295641*PED	01/10/2022					
001	9687443*PED	01/10/2022					

https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021770&Appl_type=N

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
Your search did not return any results		

[View a list of all patent use codes \(results_patent.cfm\)](#)

[View a list of all exclusivity codes \(results_exclusivity.cfm\)](#)



https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product No=001&Appl No=021770&Appl type=N